Tislelizumab Combined With Neoadjuvant Radiotherapy and Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma.

Inclusion Criteria:

1. Age 18-75
2. Histologically or cytologically confirmed resectable squamous-cell esophageal cancer (cT1-2N+/ cT3-4aN0-3M0)
3. Eastern Cooperative Oncology Group (ECOG) status 0-1
4. Signed written informed consent prior to the implementation of any trial-relatedrocedures
5. Adequate organ function, evidenced by laboratory results with no contraindications tochemotherapy Absolute neutrophil count ≥ 1,500 х109/l Thrombocytes ≥ 100 х 109/lHemoglobin ≥ 90 mg/l Creatinine ≤ 1.5 x ULN or creatinine clearance (calculated usingthe Cockcroft-Gault formula) ≥40 mL/min Alanine aminotransferase (ALT) and aspartateaminotransferase (AST) > 2.5 x upper limit of normal (ULN) Alkaline phosphatase (ALP) > 5 x ULN Bilirubin > 1.5 х ULN

Exclusion Criteria:

1. Patients diagnosed with any other malignant tumor
2. Patients at risk for tracheoesophageal fistula or aortoesophageal fistula
3. Have received prior therapy with: chemotherapy, radiation therapy,immune checkpointinhibitor
4. Insufficient caloric and/or fluid intake despite consultation with a dietitian and/ortube feeding
5. Have an active infection requiring systemic therapy that has not resolved 3 days (simple infection, such as cystitis) to 7 days (severe infection, such aspyelonephritis) before the first dose of trial treatment
6. Patients who cannot tolerate chemoradiotherapy or surgery due to severe cardiac, lungdysfunction
7. A history of interstitial lung disease or non-infectious pneumonia
8. Active autoimmune disease with systemic therapy (ie, use of disease modifiers,corticosteroids, or immunosuppressive drugs) in the past 2 years
9. Known history of human immunodeficiency virus (HIV) infection (i.e., positive for HIV 1/2 antibody) and various viral hepatitis infections
10. Patients who have received allogeneic stem cell or solid organ transplantation
11. Women during pregnancy or lactation